Atom Bioworks Inc.
Cary, NC
- UEI
- ZGKNGJMR7185
- CAGE
- 8H9A4
- SAM.gov registration
- Active through
Company facts
- Self-certified in SAM.gov
- Entity structure
- Corporate Entity (Not Tax Exempt)
- Other NAICS codes in SAM.gov
- SAM.gov registration date
- Physical address
- 1201 Riggins Mill Rd, Cary, NC 27519, USA
- Website
- atombioworks.com
- Founded
- 2019
- Employees
- 1-10
- Estimated annual revenue
- $1M-$10M
- Industry
-
- Consumer Discretionary
- Media
- Advertising
- SIC code
- 73 Business Services
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Grant awards
Similar vendors
| Vendor | Location | Primary NAICS |
|---|---|---|
| Firebird Biomolecular Sciences LLC | Alachua, FL | 541714 Research and Development in Biotechnology (except Nanobiotechnology) |
| Avery Bio Corporation | San Diego, CA | 541714 Research and Development in Biotechnology (except Nanobiotechnology) |
| Innotech Precision Medicine, Inc. | Boston, MA | 541714 Research and Development in Biotechnology (except Nanobiotechnology) |
| Dotquant LLC | Shoreline, WA | — |
| Gate Scientific, Inc. | Milpitas, CA | 334516 Analytical Laboratory Instrument Manufacturing |
About the company
Atom Bioworks Inc. is a startup company that specializes in DNA nanostructures and develops programmable DNA nanomaterial to power rapid diagnostic tests and effective cancer treatments, focusing on DNA hacking and nanoscale precision medicine. Atom Bioworks Inc. has been registered in SAM.gov, the federal System for Award Management, since November 13, 2019 as a corporate for-profit entity eligible to receive federal awards.
Atom Bioworks Inc. has received multiple federal grant awards from agencies such as the National Science Foundation and the National Institutes of Health to develop rapid diagnostic tests using its proprietary DNA nanostructure technology. In 2022, the company was awarded a $998,507 cooperative agreement from NSF's Technology, Innovation, and Partnerships program to build a preclinical prototype of a lateral flow COVID-19 test based on its Pattern-Recognition Enhanced Sensing and Therapeutics (PEST) concept, which uses algorithmically-designed structural DNA to form traps that can detect and bind to viral surface proteins, generating visual signals within minutes without need for nucleic acid preprocessing or amplification. Additionally, in 2020, NIH awarded Atom Bioworks a $5.1 million grant to develop a saliva-based SARS-CoV-2 detection assay utilizing DNA star biosensors designed to bind to the distinct surface antigen patterns of viruses. The company had also previously received a $248,368 NSF SBIR Phase I grant in 2020 for initial research on its structural DNA biosensor technology for rapid COVID-19 sensing.
Quick answers
Is Atom Bioworks Inc. registered in SAM.gov?
Yes. Atom Bioworks Inc.'s SAM.gov registration is active through March 3, 2027.
What is Atom Bioworks Inc.'s most recent federal award?
Atom Bioworks Inc.'s most recent federal grant award is Sbir phase II: covid-19 rapid sensing using structural DNA biosensors (2127436), from National Science Foundation, on August 1, 2022.
On GovTribe
See Atom Bioworks Inc.'s full federal record
- Federal grant awards
- Funding analysis by agency, NAICS and set-aside
- Similar vendors